{
  "docId": "019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "docSlug": "4fd785179c9b78e08eb8c823d8e306e6",
  "documentTitle": "argenx SE | Results Presentation Deck | 24 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 24,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide compares clinical outcomes (CR/CRc rates) for different patient cohorts and mentions a future decision point based on the ELEVATE trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f8c0-72fa-b47b-4b134ca99d3b/14",
  "deckHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "deckJsonHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b.json",
  "deckAnchorHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.18,
        "x": 0.36,
        "y": 0.72
      },
      "kind": "callout",
      "text": "46.2% Adverse Risk Classification (ELN)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a5e989-c070-430b-8916-e4d42d1e715a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.09,
        "y": 0.42
      },
      "kind": "chart",
      "text": "CR Rates table showing ITT and patients with >= 2 cycles",
      "attrs": null,
      "subkind": "table",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7bc05d8-9751-450a-8dff-de9159e7d4c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.66,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase 1b ELEVATE Trial in Triple Combination: cusatuzumab + azacitidine + venetoclax",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3adf142f-9e34-4892-8eff-d54805eeca70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "metric",
      "text": "30-day mortality: 5/52 (9.6%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "471e3d48-6cd1-4f76-ad92-fe71a32deff1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.66,
        "y": 0.63
      },
      "kind": "paragraph",
      "text": "Decision to initiate additional studies will be determined following review of data from ELEVATE",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d836ce38-2390-49ef-b6c8-7ec866c3db92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "subtitle",
      "text": "Newly diagnosed elderly AML patients who are unfit for intensive chemotherapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dd61ab6-fa9a-460c-a405-81cac0a04140",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Cusatuzumab Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87311667-5b06-4b2a-858e-7a7f93acaef6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "75721239-1041-4fe6-8eab-446d817772cd",
      "evidence": "Slides 13 and 22 discuss the need for new therapies and the potential of Efgartigimod.",
      "position": 0,
      "objective": "Highlighting the cost of inaction for MG patients.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}